Nuvation Bio (NYSE:NUVB – Free Report) had its price objective upped by HC Wainwright from $10.00 to $11.00 in a research ...

HC Wainwright upped their FY2024 earnings estimates for Axsome Therapeutics in a research note issued to investors on Tuesday ...

H.C. Wainwright analysts have reduced the price target for ALX Oncology (NASDAQ:ALXO) shares to $5 from the previous $25 ...

H.C. Wainwright adjusted its price target for Lexaria Bioscience (NASDAQ:LEXX) to $7.00, down from the previous target of $10.00, while maintaining a Buy rating on the company's shares. With the stock ...

H.C. Wainwright raised the firm’s price target on LSI Industries (LYTS) to $30 from $20 and keeps a Buy rating on the shares. The firm cites ...

H.C. Wainwright raised the firm’s price target on ArriVent Biopharma (AVBP) to $39 from $36 and keeps a Buy rating on the ...

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Lexaria Bioscience (LEXX) to $7 from $10 and keeps a Buy rating on the ...

H.C. Wainwright lowered the firm’s price target on Jasper Therapeutics (JSPR) to $40 from $60 and keeps a Buy rating on the shares after the company announced initial data from the BEACON study ...

H.C. Wainwright raised the firm’s price target on Monopar Therapeutics (MNPR) to $40 from $22 and keeps a Buy rating on the ...

H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation and an $11 per share target on Thursday, despite an over 38% drop ...

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...

BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a leader in blockchain infrastructure and technology, has announced its ...